UPDATE 1-Marathon Pharma to sell Duchenne drug to PTC Therapeutics

March 16 (Reuters) - Marathon Pharmaceuticals LLC, under intense pressure from U.S. lawmakers for the hefty price tag on its Duchenne muscular dystrophy drug, has agreed to sell the rights to the recently-approved treatment to PTC Therapeutics Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.